Shorter immunotherapy duration for advanced melanoma shows comparable disease control in UK DANTE… EP News Bureau Jun 5, 2025 UK-led phase III trial reports similar disease control at 12 months versus two years of immunotherapy for inoperable late-stage…
TAGRISSO reduces disease progression or death by 84 % in Stage III EGFR-mutated lung cancer vs.… EP News Bureau Jun 3, 2024 First and only EGFR inhibitor and targeted treatment to show benefit in stage III setting, extending progression-free survival…
